Cognition Therapeutics完成与FDA就Zervimesine治疗路易体痴呆的C类会议

美股速递
Jan 27

Cognition Therapeutics, Inc宣布,已顺利完成与美国食品药品监督管理局就Zervimesine针对路易体痴呆适应症召开的C类会议。此次会议标志着该药物研发进程中的重要里程碑。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10